Kerri Fitzgerald

DocwireNews

Researchers have hypothesized that when patients experience adverse events (AEs) upon switching from a reference biologic to a biosimilar product, a nocebo effect can occur&mdash;a detrimental effect on health produced by psychological or psychosomatic factors such as negative expectations of treatment or prognosis. The researchers conducted a literature review to evaluate if patient and/or physician knowledge of a switch from a reference biologic product to a biosimilar product was associated with an increase in AEs that may produce a nocebo effect. The results were published in the <a href="https://www.ncbi.nlm.nih.gov/pubmed/30247100">Journal of Managed Care &amp; Specialty Pharmacy</a>.Researchers assessed Medline, PubMed, and Embase to identify studies reporting efficacy and safety outcomes of a switch from a reference product to a biosimilar product, including studies of U.S. Food and Drug Administration-approved biosimilars products: adalimumab, bevacizumab, etanercept, and infliximab. They used descriptive statistics to quantify subjective and objective complications in double-blind, single-blind, or open-label studies.They analyzed data from 31 double-blind and open-label studies that included 3,271 patients who were switched from originator to biosimilar infliximab (28 studies; 2,956 patients; 2 double-blind studies) or from originator to biosimilar etanercept (3 studies; 315 patients; 2 double-blind studies).The median discontinuation rates for any reason were 14.3% (range = 0.0-33.3%) in open-label studies compared with 6.95% (range = 5.2-11.0%) in double-blind studies. Discontinuation rates for AEs were 5.6% (range = 0.0-24.2%) in open-label studies versus 3.1% (range = 2.0-5.2%) in double-blind studies, &ldquo;suggesting [that] the nocebo effect does affect biosimilar adoption,&rdquo; according to the authors. Discontinuation rates for lack of efficacy were 6.45% (range = 0.0-18.1%) in open-label studies versus 1.2% (range = 1.2-1.2%) in double-blind studies.Subgroup analyses of antidrug antibody development and infusion reactions were similar between open-label and double-blind studies. Discontinuation rates for any reason, for AEs, and for lack of efficacy were generally higher in open-label trials compared with double-blind trials. Etanercept biosimilar discontinuation rates for any reason were similar between study designs; however, incidences of injection-site reactions and discontinuation due to AEs were higher in double-blind studies compared with open-label studies.&ldquo;Current evidence is insufficient to confirm a biosimilar nocebo effect, although higher discontinuation rates in infliximab biosimilar open-label studies support this theory,&rdquo; the authors concluded, noting the need for additional studies on the subject.

Bradley Marder, MD

Joel M. Topf, MD, FACP

Gout Studies: Transplant Waitlisting and Bone Erosion

NKF Spring Clinical Meetings 2025

Jayme Locke, MD, MPH

The Promise of Xenotransplantation

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Latest News

Literature Review Inconclusive on “Nocebo” Effect of Biosimilars

Oncology

Researchers have hypothesized that when patients experience adverse events (AEs) upon switching from a reference biologic to a biosimilar product, a nocebo effect can ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe